Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-07, Stock:NVS, The news for the past five days is as follows:
2018-01-31: NEWS1: A Key Update on Gilead Sciences’ ZUMA-3 Study.NEWS2: Array BioPharma’s ARRY-382 and ARRY-797.NEWS3: Wall Street Is More Optimistic about JNJ Stock after 4Q17 Results.NEWS4: Momenta Up on FDA's Amendment of McPherson Compliance Status.NEWS5: Momenta Up on FDA's Amendment of McPherson Compliance Status.NEWS6: The Best Arthritis Drug/Treatment Stocks on the Market Right Now.NEWS7: The Best Arthritis Drug/Treatment Stocks on the Market Right Now.NEWS8: What Else Could Drive Gilead’s Long-Term Growth?.NEWS9: The Swiss Stock Market Finished With A Substantial Loss.NEWS10: The Swiss Stock Market Finished With A Substantial Loss.NEWS11: Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX.NEWS12: Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX.
2018-02-01: NEWS1: Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A..NEWS2: Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer.NEWS3: Novartis Closes Subsequent Offering Period Of Tender Offer For AAAP.NEWS4: Novartis Closes Subsequent Offering Period Of Tender Offer For AAAP.NEWS5: Commentary: How We Can Bring Health Care to the World’s Underserved.NEWS6: Analyzing Celgene’s Performance in 4Q17.NEWS7: Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa.NEWS8: Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa.NEWS9: GSK Projects Modest Long-Term Revenue Growth for Vaccines Portfolio.NEWS10: The Swiss Stock Market Fell On Pharma Weakness.NEWS11: The Swiss Stock Market Fell On Pharma Weakness.NEWS12: Stada Names Sandoz Manager as Fifth CEO Since 2016.
2018-02-02: NEWS1: Novartis’s 4Q17 Earnings: Innovative Medicines Business.NEWS2: Biogen’s Tecfidera and Tysabri: 4Q17 Performance.NEWS3: Novartis’s 4Q17 Earnings: Segment-Wise Revenues.NEWS4: Novartis’s 4Q17 Revenues and Fiscal 2017 Revenues.NEWS5: Biogen: How It Performed in 4Q17.NEWS6: Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft.NEWS7: Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft.NEWS8: AstraZeneca: Analyst Ratings and Recommendations.NEWS9: Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?.NEWS10: Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?.NEWS11: Cell Therapy Market Could Boost Celgene’s Long-Term Growth.NEWS12: AstraZeneca’s 4Q17 Estimates: Segment Revenues.NEWS13: Celgene: Pomalyst and Otezla’s Revenue Trends in 4Q17.NEWS14: AstraZeneca’s 4Q17 Earnings: Analyst Estimates.NEWS15: How Has Johnson & Johnson Stock Performed Recently?.NEWS16: The Swiss Stock Market Extends Losing Streak.NEWS17: The Swiss Stock Market Extends Losing Streak.
2018-02-05: NEWS1: Greek govt alleges official ties to drug bribery scandal.NEWS2: 3 Top Pharmaceutical Stocks to Buy Now.NEWS3: 3 Top Pharmaceutical Stocks to Buy Now.NEWS4: Novartis’s Valuations after Its 4Q17 Earnings.NEWS5: Novartis’s 4Q17 Earnings: Alcon Business.NEWS6: GSK Is Focused on Innovative Assets in Oncology Research Pipeline.NEWS7: Novartis’s 4Q17 Earnings: Sandoz Business.NEWS8: How Biogen’s Biosimilars and Interferons Performed in 4Q17.NEWS9: Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline.NEWS10: The Swiss Stock Market Continues To Sell-Off.NEWS11: The Swiss Stock Market Continues To Sell-Off.
2018-02-06: NEWS1: Roche Reports Positive Data From Tecentriq-Avastin Study.NEWS2: Roche Reports Positive Data From Tecentriq-Avastin Study.NEWS3: Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM.NEWS4: Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM.NEWS5: The Diseases We Aren’t Curing—And Why.NEWS6: How Did Kalydeco Perform in 4Q17 and 2017?.NEWS7: Analysts’ Recommendations for Novartis after Its 4Q17 Earnings.NEWS8: The Swiss Stock Market Sank Below The 9,000 Point Level.NEWS9: The Swiss Stock Market Sank Below The 9,000 Point Level.NEWS10: Xtandi Prospers, One Down, One To Go For AMAG, There's Reason For CORT's Fall.NEWS11: Xtandi Prospers, One Down, One To Go For AMAG, There's Reason For CORT's Fall.

Answer: Decrease